Genetic Technologies gets tough
Monday, 14 July, 2008
Genetic Technologies (ASX: GTG) will enforce its exclusive rights to perform diagnostic testing of the BRCA1 and BRCA2 breast cancer genes in Australia and New Zealand.
The company has been paying ongoing licence fees to Myriad Genetics for exclusive rights to perform diagnostic testing but has been allowing other service providers to perform BRCA testing for the last five years.
Genetic Technologies said in a statement it was now enforcing those exclusive rights, preventing several laboratories throughout the country from performing the test.
It said it had invested several million dollars in a high-throughput molecular diagnostic laboratory and had reduced turnaround time to four weeks.
How a tiny worm changed a decade of scientific thinking
A tiny roundworm has helped University of Queensland scientists rethink the way sensory nerve...
A scientist, a cooler and a long-haul flight in the fight against MND
Early in January 2026, neuroscientist Dr Rachael Dunlop boarded a flight from Sydney to the US...
Mini lung organoids could help test new treatments
Scientists have developed a simple method for automated the manufacturing of lung organoids...
